BioGaia AB (BIOG-B) Fair Value & Analysis
Healthcare · SE · Market cap 12.6B SEK
Fair value as of: Jul 19, 2026
From 24 valuation models · updated 2 days ago
Share price +0.7% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 90.78 – kr 134.90 · fair‑value band kr 54.06 – kr 95.08 · the kr 119.00 price screens above the kr 70.27 fair value. As of Jul 19, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
BioGaia AB (BIOG-B) currently trades at kr 119.00, while our model-based Fair Value estimate is kr 70.27, implying the stock looks roughly 41.0% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, BioGaia AB generated revenue of 1.5B SEK at a net margin of 21.5%. Revenue grew 1.7% year over year. It earns a return on equity of 20.9%. The balance sheet holds a net cash position of 801M SEK. Fundamentals as of Jul 19, 2026
Our scenario range runs from kr 54.06 (bear case) to kr 95.08 (bull case); at kr 119.00, the current price sits above that range. The share trades about 13% below its 52-week high and 32% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside, at -41%, BIOG-B screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.
About the company
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BioGaia AB reported revenue of kr 1.5B in FY2025 versus kr 785M in FY2021, a compound +18.3%/yr. Reported net income was kr 333M in FY2025, compounding +14.1%/yr from FY2021.
Is BIOG-B fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Lupin Limited LUPIN | ₹2,268 | ₹2,697 | +19% |
| Mankind Pharma Limited MANKIND | ₹2,336 | ₹1,068 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BioGaia AB (BIOG-B) undervalued?
What is the fair value of BIOG-B?
What is the quality score of BIOG-B?
What is the revenue of BioGaia AB (BIOG-B)?
What is the net profit margin of BIOG-B?
Does BioGaia AB pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full BioGaia AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.